M. Balak

发表

Enhanced Motor Function by Training in Spinal Cord Contused Rats Following Radiation Therapy

V. Edgerton, R. Ichiyama, Melissa Potuzak, 2009, PloS one.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

William Pao, Stephen Broderick, Lu Wang, 2007, Proceedings of the National Academy of Sciences.

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

William Pao, Marc Ladanyi, Gregory J Riely, 2006, Clinical Cancer Research.

The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor

W. Pao, Y. Gong, M. Balak, 2007 .

Response to CCR-07-0070

W. Pao, Y. Gong, M. Balak, 2007, Clinical Cancer Research.

Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib.

M. Ladanyi, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Joshua M. Korn, Franziska Michor, Derek Y. Chiang, 2015, Nature Medicine.

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

M. Ladanyi, W. Pao, Gregory Riely, 2008, Clinical Cancer Research.

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

W. Pao, N. Rosen, D. Solit, 2007, PloS one.

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

W. Pao, K. Politi, R. Somwar, 2007, PLoS medicine.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

H. Huynh, K. Soo, Manway Liu, 2015, Molecular Cancer Therapeutics.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

H. Huynh, K. Soo, Manway Liu, 2015, Molecular Cancer Therapeutics.

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity

Joshua M. Korn, J. Korn, G. Caponigro, 2017, Molecular Cancer Research.

Running Title : Characterizing BRAF Inhibitor-associated MEK Mutants Corresponding

Joshua M. Korn, J. Korn, G. Caponigro, 2017 .

NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors

M. Ladanyi, M. Kris, W. Pao, 2006 .

Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer.

William Pao, Marc Ladanyi, Vincent A. Miller, 2006 .

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor. Authors' reply

S. Toyooka, W. Pao, K. Kiura, 2007 .